{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:51:11Z","timestamp":1793724671158,"version":"4.6.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Siriraj Foundation","award":["D002735"],"award-info":[{"award-number":["D002735"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-25209-8","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T11:24:49Z","timestamp":1763724289000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The association of defective pleural sRAGE production with the recurrence of malignant pleural effusion after Talc pleurodesis"],"prefix":"10.1038","volume":"15","author":[{"given":"Kittipong","family":"Maneechotesuwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chakchawis","family":"Kanokkantapong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalit","family":"Boonpromkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jirawat","family":"Assawabhumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Adcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"25209_CR1","doi-asserted-by":"crossref","unstructured":"Bibby, A. C. et al. ERS\/EACTS statement on the management of malignant pleural effusions. Eur. Respir. J. 52(2018).","DOI":"10.1183\/13993003.00349-2018"},{"issue":"Suppl 2","key":"25209_CR2","doi-asserted-by":"publisher","first-page":"ii32","DOI":"10.1136\/thx.2010.136994","volume":"65","author":"ME Roberts","year":"2010","unstructured":"Roberts, M. E. et al. Management of a malignant pleural effusion: British thoracic society pleural disease guideline 2010. Thorax 65(Suppl 2), ii32\u201340 (2010).","journal-title":"Thorax"},{"key":"25209_CR3","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1001\/jama.2012.5543","volume":"307","author":"NA Maskell","year":"2012","unstructured":"Maskell, N. A. Treatment options for malignant pleural effusions: patient preference does matter. JAMA 307, 2432\u20132433 (2012).","journal-title":"JAMA"},{"key":"25209_CR4","doi-asserted-by":"crossref","unstructured":"Santos, P. S., Marques, M. A., Cruz, C., Monteiro, H. & Fradinho, F. Predictors of talc slurry pleurodesis success in patients with malignant pleural effusions. Rev. Port Pneumol. 23, 216\u2013220 (2017).","DOI":"10.1016\/j.rppnen.2017.01.008"},{"key":"25209_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.ejcts.2005.12.025","volume":"29","author":"C Tan","year":"2006","unstructured":"Tan, C., Sedrakyan, A., Browne, J., Swift, S. & Treasure, T. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur. J. Cardiothorac. Surg. 29, 829\u2013838 (2006).","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"25209_CR6","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/1097-0142(197404)33:4<916::AID-CNCR2820330405>3.0.CO;2-U","volume":"33","author":"CB Anderson","year":"1974","unstructured":"Anderson, C. B., Philpott, G. W. & Ferguson, T. B. The treatment of malignant pleural effusions. Cancer 33, 916\u2013922 (1974).","journal-title":"Cancer"},{"key":"25209_CR7","first-page":"CD010529","volume":"4","author":"A Dipper","year":"2020","unstructured":"Dipper, A. et al. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst. Rev. 4, CD010529 (2020).","journal-title":"Cochrane Database Syst. Rev."},{"key":"25209_CR8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1080\/17476348.2020.1746647","volume":"14","author":"M Hassan","year":"2020","unstructured":"Hassan, M., Gadallah, M., Mercer, R. M., Harriss, E. & Rahman, N. M. Predictors of outcome of pleurodesis in patients with malignant pleural effusion: a systematic review and meta-analysis. Expert Rev. Respir Med. 14, 645\u2013654 (2020).","journal-title":"Expert Rev. Respir Med."},{"key":"25209_CR9","doi-asserted-by":"publisher","first-page":"1336191","DOI":"10.3389\/fonc.2024.1336191","volume":"14","author":"A Fan","year":"2024","unstructured":"Fan, A. et al. HMGB1\/RAGE axis in tumor development: unraveling its significance. Front. Oncol. 14, 1336191 (2024).","journal-title":"Front. Oncol."},{"key":"25209_CR10","doi-asserted-by":"publisher","first-page":"101958","DOI":"10.1016\/j.redox.2021.101958","volume":"42","author":"JD Erusalimsky","year":"2021","unstructured":"Erusalimsky, J. D. The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes. Redox Biol. 42, 101958 (2021).","journal-title":"Redox Biol."},{"key":"25209_CR11","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1096\/fj.08-109033","volume":"22","author":"A Raucci","year":"2008","unstructured":"Raucci, A. et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the Sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 22, 3716\u20133727 (2008).","journal-title":"FASEB J."},{"key":"25209_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2174\/156652407783220697","volume":"7","author":"CD Logsdon","year":"2007","unstructured":"Logsdon, C. D., Fuentes, M. K., Huang, E. H. & Arumugam, T. RAGE and RAGE ligands in cancer. Curr. Mol. Med. 7, 777\u2013789 (2007).","journal-title":"Curr. Mol. Med."},{"key":"25209_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/carcin\/bgh333","volume":"26","author":"B Bartling","year":"2005","unstructured":"Bartling, B., Hofmann, H. S., Weigle, B., Silber, R. E. & Simm, A. Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 26, 293\u2013301 (2005).","journal-title":"Carcinogenesis"},{"key":"25209_CR14","doi-asserted-by":"publisher","unstructured":"Hajizadeh-Sharafabad, F. et al. Associations of Circulating advanced glycation end products and their soluble receptors with cancer risk: A systematic review and meta-analysis of observational studies. Glycoconj. J. 41, 35\u201346. https:\/\/doi.org\/10.1007\/s10719-024-10147-w (2024).","DOI":"10.1007\/s10719-024-10147-w"},{"key":"25209_CR15","doi-asserted-by":"publisher","first-page":"8749","DOI":"10.1007\/s13277-014-2122-7","volume":"35","author":"L He","year":"2014","unstructured":"He, L. et al. Circulating soluble advanced glycation end product is inversely associated with the significant risk of developing cancer: evidence from a meta-analysis. Tumour Biol. 35, 8749\u20138755 (2014).","journal-title":"Tumour Biol."},{"key":"25209_CR16","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1001\/jama.2015.16840","volume":"314","author":"NM Rahman","year":"2015","unstructured":"Rahman, N. M. et al. Effect of opioids vs NSAIDs and larger vs smaller chest tube size on pain control and pleurodesis efficacy among patients with malignant pleural effusion: the TIME1 randomized clinical trial. JAMA 314, 2641\u20132653 (2015).","journal-title":"JAMA"},{"key":"25209_CR17","doi-asserted-by":"publisher","first-page":"1060495","DOI":"10.3389\/fonc.2022.1060495","volume":"12","author":"S Liu","year":"2022","unstructured":"Liu, S., Li, Y., Yuan, M., Song, Q. & Liu, M. Correlation between the Warburg effect and progression of triple-negative breast cancer. Front. Oncol. 12, 1060495 (2022).","journal-title":"Front. Oncol."},{"key":"25209_CR18","doi-asserted-by":"publisher","first-page":"ra73","DOI":"10.1126\/scisignal.2000431","volume":"2","author":"T Hitosugi","year":"2009","unstructured":"Hitosugi, T. et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal. 2, ra73 (2009).","journal-title":"Sci. Signal."},{"key":"25209_CR19","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1002\/jcp.30125","volume":"236","author":"J Xue","year":"2021","unstructured":"Xue, J. et al. HMGB1 as a therapeutic target in disease. J. Cell. Physiol. 236, 3406\u20133419 (2021).","journal-title":"J. Cell. Physiol."},{"key":"25209_CR20","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.3389\/fimmu.2020.02027","volume":"11","author":"AC Soloff","year":"2020","unstructured":"Soloff, A. C. et al. HMGB1 promotes myeloid egress and limits lymphatic clearance of malignant pleural effusions. Front. Immunol. 11, 2027 (2020).","journal-title":"Front. Immunol."},{"key":"25209_CR21","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1007\/s00262-023-03564-7","volume":"72","author":"Q Hu","year":"2023","unstructured":"Hu, Q., Wang, R., Zhang, J., Xue, Q. & Ding, B. Tumor-associated neutrophils upregulate PANoptosis to foster an immunosuppressive microenvironment of non-small cell lung cancer. Cancer Immunol. Immunother. 72, 4293\u20134308 (2023).","journal-title":"Cancer Immunol. Immunother"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25209-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25209-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25209-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T11:24:51Z","timestamp":1763724291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25209-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["25209"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-25209-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study involves human participants and was approved by the Institutional Review Board of Siriraj Hospital (number of approval: Si 771\/2018). Participants gave informed consent to participate in the study before taking part.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"41223"}}